We are excited to present case reports from our ongoing #cartcelltherapy trials in #stiffpersonsyndrome, #myastheniagravis, and #multiplesclerosis during our symposium at #ECTRIMS2024, together with posters on KYSA-6 and KYSA-7 study design. Read more in our press release here: https://lnkd.in/gcaMUEpN
Kyverna Therapeutics
Biotechnology Research
Emeryville, California 15,739 followers
Harnessing the power of cell therapy in autoimmune disease.
About us
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
- Website
-
http://kyvernatx.com
External link for Kyverna Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Emeryville, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- cell therapy, autoimmune, lupus, multiple sclerosis, systemic sclerosis, scleroderma, myasthenia gravis, CAR T-cell, and stiff-person syndrome
Locations
-
Primary
5980 Horton St
Suite 550
Emeryville, California 94608, US
Employees at Kyverna Therapeutics
Updates
-
Excited to present our latest data this Wednesday at #ECTRIMS2024 and advance the knowledge on the potential of #cartcelltherapy in neurologic #autoimmunedisease.
-
Today, we are excited to welcome Warner Biddle as our Chief Executive Officer. With over 30 years of global experience in senior and franchise leadership roles, Warner has an outstanding track record of steering #biotech companies through pivotal growth phases and transformative milestones. Warner’s leadership and extensive industry knowledge will be instrumental as he leads us through our next stage of growth as our clinical-stage programs in #cartcelltherapy and #autoimmunediseases continue to advance. Welcome to the team, Warner! Read more in our press release: https://lnkd.in/gxi2bWkf
-
Proud to have our President, Research and Development, Dominic Borie, M.D., Ph.D. presenting at the 13th HUHRD (Hanyang University Hospital for Rheumatic Diseases) International Symposium to advance the knowledge around #cartcelltherapy in the treatment of #autoimmunedisease. For more information: https://lnkd.in/gvhsdvum #KYV101 #AskKyverna
-
Proud to have been the 'Featured Presenter' at the Cell Therapy Manufacturing session during the 16th Annual Bioprocessing Summit in Boston last week. The event brought together leaders from industry and academia, where our clinical product data saw significant interest. #CARTCellTherapy #KYV101
-
Thank you Shamekka Marty PMP, CSM for being a voice for the voiceless and a fierce advocate for patient and caregiver education about potential shifts in the treatment paradigm for #autoimmunedisease. It was a pleasure hosting you at the Village.
2023 Sequioa Project Patient Volunteer of the Year| Cybersecurity Consultant | Healthcare Interoperability | Patient Advocate | Speaker | Connector | IT Project Manager | Certified Scrum Master
Thank you, Kyverna Therapeutics, for the opportunity to speak with you today about my experiences living with #lupus. It's vital that we work together to reach more individuals and change the stigma surrounding clinical trials for #CAR T-cell therapy, as well as the importance of patient informed consent in regards to wearable devices. I truly appreciate the leadership within your company for engaging with #patient advocates; it shows a commitment to understanding our community's needs. I'm excited to see how dedicated your team is to improving treatments for lupus and exploring the possibility of a cure. I look forward to learning more about the studies on CAR T-cell therapy and its impact on #autoimmune diseases. #cartcelltherapy #lupus #autoimmunedisease #ms #scleraderma #patientadvocate #informedconsent
-
Pleased to share we have received our second U.S. FDA RMAT Designation for #KYV101 in the treatment of patients with progressive myasthenia gravis. The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program. The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101. #myastheniagravis #cartcelltherapy https://lnkd.in/g7J3AQ5x
-
Prof Dimitrios Mougiakakos recently visited the Kyverna village. It was encouraging to hear him say:" I am impressed by the work and cooperative spirit of the Kyverna team. It's great to see the current clinical experience building, in particular the emerging safety data. We have not seen severe CRS and ICANs in patients with autoimmune disease treated with KYV-101."
-
Carrie Robinette has #StiffPersonSyndrome, though getting a diagnosis wasn’t quick. Few doctors have seen Stiff-Person Syndrome, let alone know how to treat it. Kyverna’s business unit head of rare diseases, Sham Dholakia, recently spoke with Carrie for Business Insider about the challenges doctors face in diagnosing SPS. https://lnkd.in/giXaW9QB
-
Today is National Intern Day! At Kyverna Therapeutics, we are thrilled to celebrate our four amazing 2024 summer interns. Throughout their internship, each of them has shown exceptional talent and an incredible commitment to learning. To our interns, thank you for your dedication and passion to our mission of harnessing the power of CAR-T Cell Therapy for autoimmune diseases. We look forward to your future achievements and are proud to have been part of your professional development. Tatum Laird Kieran V. Max McLeod Xinyang Chen #NationalInternDay